Rock Soffer net worth and biography

Rock Soffer Biography and Net Worth

Director of Longeveron
Rock Soffer joined Longeveron’s Board of Directors in March 2020. Mr. Soffer is President, Special Project Division at Turnberry Associates, where he oversees leasing, asset acquisitions, zoning and site approvals, as well as the development of other specialty projects. He has experience in managing and securing financing for complex projects, as well as overseeing a number of developments in Florida, such as the redevelopment of an almost 200,000 square-foot open-air lifestyle shopping center in Aventura. In addition, Mr. Rock Soffer was tasked with overseeing the referendum for the new 800-key Miami Beach Convention Center luxury hotel. Upon completion, the privately-funded property will be the cornerstone of the Convention Center District in Miami Beach. Mr. Rock Soffer is an advocate for responsible, environmentally sustainable development. He is actively involved in his local community and sits on the boards of AYITI Community Trust, and the Institute of Contemporary Art Miami.

What is Rock Soffer's net worth?

The estimated net worth of Rock Soffer is at least $2.76 million as of May 20th, 2022. Mr. Soffer owns 684,351 shares of Longeveron stock worth more than $2,764,778 as of September 26th. This net worth estimate does not reflect any other investments that Mr. Soffer may own. Learn More about Rock Soffer's net worth.

How do I contact Rock Soffer?

The corporate mailing address for Mr. Soffer and other Longeveron executives is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. Longeveron can also be reached via phone at 305-909-0840 and via email at [email protected] Learn More on Rock Soffer's contact information.

Has Rock Soffer been buying or selling shares of Longeveron?

Rock Soffer has not been actively trading shares of Longeveron during the last ninety days. Most recently, Rock Soffer sold 8,000 shares of the business's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $7.78, for a transaction totalling $62,240.00. Following the completion of the sale, the director now directly owns 676,351 shares of the company's stock, valued at $5,262,010.78. Learn More on Rock Soffer's trading history.

Who are Longeveron's active insiders?

Longeveron's insider roster includes James Clavijo (CFO), Geoff Green (CEO), Joshua Hare (Insider), Paul Lehr (General Counsel), and Rock Soffer (Director). Learn More on Longeveron's active insiders.

Are insiders buying or selling shares of Longeveron?

During the last year, Longeveron insiders bought shares 7 times. They purchased a total of 28,135 shares worth more than $100,864.30. During the last year, insiders at the sold shares 4 times. They sold a total of 72,377 shares worth more than $627,158.30. The most recent insider tranaction occured on June, 3rd when CFO James Clavijo sold 36,955 shares worth more than $305,248.30. Insiders at Longeveron own 41.6 % of the company. Learn More about insider trades at Longeveron.

Information on this page was last updated on 6/3/2022.

Rock Soffer Insider Trading History at Longeveron

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2022Sell8,000$7.78$62,240.00676,351View SEC Filing Icon  
5/20/2022Sell7,500$8.06$60,450.00684,351View SEC Filing Icon  
10/13/2021Buy12,000$3.76$45,120.00View SEC Filing Icon  
10/11/2021Buy3,900$3.45$13,455.00View SEC Filing Icon  
2/12/2021Buy100$8.05$805.00View SEC Filing Icon  
See Full Table

Rock Soffer Buying and Selling Activity at Longeveron

This chart shows Rock Soffer's buying and selling at Longeveron by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Longeveron Company Overview

Longeveron logo
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Read More

Today's Range

Now: $4.04
Low: $3.89
High: $4.07

50 Day Range

MA: $5.44
Low: $3.97
High: $6.77

2 Week Range

Now: $4.04
Low: $2.84
High: $45.00

Volume

39,500 shs

Average Volume

2,072,154 shs

Market Capitalization

$84.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.04